William Looney

Carlos Morel, MD, Director for Technical Development in Health, Oswaldo Cruz Foundation

Despite the gloom, most forecasts show the US will stay atop the industry in profits for at least the next generation of products.

A Q&A with Kristin Peck, the drugmaker's Executive Vice President, Worldwide Business Development and Innovation.

What Big Pharma fails to see is how engagement in health policy is the biggest of reputation builders

More bad ideas on how to manage the healthcare burden are circulating beyond the stakeholders that initiated them

Pharma can be an insular industry, with limited capacity to gaze beyond its own narrow frame of vision

Can PhRMA's own business model synch with industry's Pharm Exec takes a closer look at PhRMA's new leadership.

"Tops in Fraud" is a ruinous moniker for pharma-a business so dependent on basic issues of trust, integrity, quality and safety

The new investigative journalism organization recently took an in-depth look at pharma with its "Dollars for Docs" report. In return, Pharm Exec takes a look back at ProPublica

The end of anther year is an appropriate time to highlight the march of time-and the transitions that accompany it

Ethical behavior can be a bridge-builder in an era where Big Pharma needs to find new partners. Is it up to the challenge?

An industry struggling to meet expectations for new science may find the best strategy is the "controlled burn."

It's back to the future in Pharm Exec's second-annual review of industry prospects in the IMS "Pharmerging 17"

The public-interest charity takes on pharma-influenced medicing and drug-resistant bacteria.

Innovation in industry has always required a strong internal champion; the danger is a process led by the risk-adverse and externally-driven stakeholder consensus called "death by faint praise." Is this really what we mean by "bold partnerships?"

Cash-rich Big Pharmas are hedging their bets to cover both segments under the rubric of "diversification." If it sticks to the wall, then buy it.

Can the combination with Schering-Plough transform the company from an also-ran to a contender in the big push for market share in the developing world?

Innovation won't happen until the industry is ready to sit down and make a big change.

In a disruptive era of change, old-fashioned intuition still counts.

The fight against cancer may be the litmus test for how regulation and private investment work together to address the disease burden.